Unknown

Dataset Information

0

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.


ABSTRACT:

Background

Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment.

Methods

Prognostic and predictive values of post-operative CEA in patients with stage II CC were evaluated with Kaplan-Meier survival curves and Cox model with interaction terms. Disease-free survival (DFS) and overall survival (OS) were estimated.

Results

Among 899 stage II CC patients, post-operative CEA was available in 867 (96.4%); and 434 (48.65%) had a high-risk stage II disease. The 3-year DFS rate was 88.5% and 78.7% in the ≤ 2.35 ng/mL and > 2.35 ng/mL group, respectively (P = 0.006). Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2.35 ng/ml (interaction term P = 0.09 and 0.03 for DFS and OS).

Conclusion

CEA is a strong prognostic factor for DFS and OS in stage II CC. In the MOSAIC trial, only high-risk stage II CC patients with post-operative CEA > 2.35 ng/mL benefited from the addition of oxaliplatin to LV5FU2.

Trial registration

NCT00275210 (January 11, 2006).

SUBMITTER: Auclin E 

PROVIDER: S-EPMC6738041 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.

Auclin Edouard E   André Thierry T   Taieb Julien J   Banzi Maria M   Van Laethem Jean-Luc JL   Tabernero Josep J   Hickish Tamas T   de Gramont Aimery A   Vernerey Dewi D  

British journal of cancer 20190712 4


<h4>Background</h4>Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment.<h4>Methods</h4>Prognostic and predictive values of post-operative CEA in patients with stage II CC  ...[more]

Similar Datasets

| S-EPMC11546770 | biostudies-literature
| S-EPMC7251078 | biostudies-literature
| S-EPMC11523985 | biostudies-literature
| S-EPMC3274510 | biostudies-literature
| S-EPMC9303075 | biostudies-literature
| S-EPMC6048031 | biostudies-literature
| S-EPMC4792578 | biostudies-literature
| S-EPMC7966838 | biostudies-literature
| S-EPMC4273673 | biostudies-literature
| S-EPMC10835817 | biostudies-literature